Literature DB >> 27053095

The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis.

Uwe Lange1, Gabriel Dischereit2, Ingo Tarner2, Klaus Frommer2, Elena Neumann2, Ulf Müller-Ladner2, Bernhard Kürten3.   

Abstract

Secondary osteoporosis is a frequent complication of rheumatoid arthritis (RA) and the result of an imbalance of catabolic and anabolic mechanisms of bone metabolism. The effects of serial low-dose radon and hyperthermia (LDRnHT) exposure in a therapeutic adit (12 applications in 3 weeks) on the serum levels of the cytokines osteoprotegerin (OPG), receptor activator of NF kappa-B ligand (RANKL), tumor necrosis factor-α (TNF-α), and also on the RANKL/OPG ratio were investigated in 25 RA patients and an age-matched control of 24 patients with osteoarthritis (OA). Cytokine measurements were performed at baseline and after completion of LDRnHT. Anti-CCP antibodies (ACPA) were measured in RA patients in parallel. Medication in both groups was limited to non-steroidal anti-inflammatory drugs, and low-dose prednisolone (16 of 24 RA patients) as needed. RA and OA patients showed a significant decrease of TNF-α levels (p < 0.001). Both groups showed significantly decreased levels of RANKL (RA: p < 0.001, OA: p < 0.01). Only the RA patients presented a significant increase of OPG (p < 0.01) and decrease of the RANKL/OPG ratio (p < 0.01), and the ACPA levels (p < 0.001). LDRnHT results in a reduction of osteocatabolic and an increase of osteoanabolic cytokines, which represents the molecular basis for inhibiting osteoclastic activity in secondary osteoporosis and explains in part the effect of LDRnHT this physical therapy modality in a key inflammatory disease. Although reduced ACPA levels were observed under the therapy and although this could potentially contribute to an osteoprotective effect, in this case, it is rather uncertain as the reduction was only minor in magnitude.

Entities:  

Keywords:  Anti-CCP antibodies (ACPA); Osteoprotegerin; Receptor activator of NF kappa-B ligand; Rheumatoid arthritis; Serial radon (adit) therapy; TNF-α

Mesh:

Substances:

Year:  2016        PMID: 27053095     DOI: 10.1007/s10067-016-3236-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  Radon therapy for the treatment of rheumatic diseases--review and meta-analysis of controlled clinical trials.

Authors:  Albrecht Falkenbach; J Kovacs; A Franke; K Jörgens; K Ammer
Journal:  Rheumatol Int       Date:  2003-12-12       Impact factor: 2.631

Review 2.  The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models.

Authors:  Elena Neumann; Steffen Gay; Ulf Müller-Ladner
Journal:  Arthritis Rheum       Date:  2005-10

3.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  [Osteoporosis - inflammatory effects on bone metabolism and fracture risk].

Authors:  G Dischereit; U Lange
Journal:  Z Orthop Unfall       Date:  2014-04-23       Impact factor: 0.923

5.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Authors:  N Bucay; I Sarosi; C R Dunstan; S Morony; J Tarpley; C Capparelli; S Scully; H L Tan; W Xu; D L Lacey; W J Boyle; W S Simonet
Journal:  Genes Dev       Date:  1998-05-01       Impact factor: 11.361

Review 6.  Rheumatic diseases: the effects of inflammation on bone.

Authors:  Nicole C Walsh; Tania N Crotti; Steven R Goldring; Ellen M Gravallese
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

7.  Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome.

Authors:  J E Fonseca; N Cortez-Dias; A Francisco; M Sobral; H Canhão; C Resende; W Castelão; C Macieira; G Sequeira; F Saraiva; J A Pereira da Silva; M Carmo-Fonseca; M Viana Queiroz
Journal:  Clin Exp Rheumatol       Date:  2005 Mar-Apr       Impact factor: 4.473

8.  [Genetic aspects of osteopenia/osteoporosis in ankylosing spondylitis].

Authors:  U Lange; J Teichmann; B Obermayer-Pietsch
Journal:  Z Orthop Unfall       Date:  2009 Sep-Oct       Impact factor: 0.923

Review 9.  CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.

Authors:  Damaris Vega; Naim M Maalouf; Khashayar Sakhaee
Journal:  J Clin Endocrinol Metab       Date:  2007-09-25       Impact factor: 5.958

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more
  13 in total

Review 1.  [Physical therapy options in rheumatic diseases: what is evidence-based?]

Authors:  U Lange; S Rehart
Journal:  Orthopade       Date:  2018-11       Impact factor: 1.087

2.  [Multimodal rheumatologic complex treatment of rheumatoid arthritis-a monocentric retrospective analysis].

Authors:  P Klemm; O Hudowenz; T Asendorf; U Müller-Ladner; U Lange; I H Tarner
Journal:  Z Rheumatol       Date:  2019-03       Impact factor: 1.372

Review 3.  Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Peng Wang; Si Li; Li-Na Liu; Tian-Tian Lv; Xiao-Mei Li; Xiang-Pei Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2017-07-11       Impact factor: 2.980

4.  Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis.

Authors:  Philipp Klemm; Ole Hudowenz; Thomas Asendorf; Gabriel Dischereit; Ulf Müller-Ladner; Uwe Lange; Ingo H Tarner
Journal:  Clin Rheumatol       Date:  2020-01-08       Impact factor: 2.980

Review 5.  [Pain reduction through physical medicine : Update on the evidence].

Authors:  Uwe Lange; Gabriel Dischereit; Philipp Moritz Klemm
Journal:  Z Rheumatol       Date:  2022-03-29       Impact factor: 1.372

6.  Temporarily increased TGFβ following radon spa correlates with reduced pain while serum IL-18 is a general predictive marker for pain sensitivity.

Authors:  Miriam Kullmann; Paul F Rühle; Alexandra Harrer; Anna Donaubauer; Ina Becker; Renate Sieber; Gerhart Klein; Claudia Fournier; Rainer Fietkau; Udo S Gaipl; Benjamin Frey
Journal:  Radiat Environ Biophys       Date:  2018-11-19       Impact factor: 1.925

7.  Endogenous anandamide and self-reported pain are significantly reduced after a 2-week multimodal treatment with and without radon therapy in patients with knee osteoarthritis: a pilot study.

Authors:  M Gaisberger; J Fuchs; M Riedl; S Edtinger; R Reischl; G Grasmann; B Hölzl; F Landauer; H Dobias; F Eckstein; M Offenbächer; M Ritter; M Winklmayr
Journal:  Int J Biometeorol       Date:  2021-03-01       Impact factor: 3.787

8.  Decrease of Markers Related to Bone Erosion in Serum of Patients with Musculoskeletal Disorders after Serial Low-Dose Radon Spa Therapy.

Authors:  Aljona Cucu; Kateryna Shreder; Daniela Kraft; Paul Friedrich Rühle; Gerhart Klein; Gerhard Thiel; Benjamin Frey; Udo S Gaipl; Claudia Fournier
Journal:  Front Immunol       Date:  2017-07-25       Impact factor: 7.561

9.  Heat-stimuli-enhanced osteogenesis using clinically available biomaterials.

Authors:  Takehiro Ota; Yoshihiro Nishida; Kunihiro Ikuta; Ryuji Kato; Eiji Kozawa; Shunsuke Hamada; Tomohisa Sakai; Naoki Ishiguro
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

Review 10.  Radon Exposure-Therapeutic Effect and Cancer Risk.

Authors:  Andreas Maier; Julia Wiedemann; Felicitas Rapp; Franziska Papenfuß; Franz Rödel; Stephanie Hehlgans; Udo S Gaipl; Gerhard Kraft; Claudia Fournier; Benjamin Frey
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.